linjc16/ctgov huggingface dataset:
Web-based Personalized Feedback for University Students

Study Overview
=================
Brief Summary
-----------------
Excessive alcohol consumption in university students continues for be a serious public health concern with a variety of negative consequences. There have been a number of different brief interventions developed to address this issue among university students. The current project will add to this literature by evaluating the use of a personalized feedback intervention (www.CheckYourDrinkingU.net; CYDU). Specifically, this trial will examine whether providing access to the CYDU will result in short-term reductions in drinking. This issue is important as use of these interventions is not a mandatory requirement for university students so the issue is whether making materials of this type available leads to any reductions in risky drinking. It is hypothesized that students provided access to the CYDU will display greater reductions in drinking at a six-week follow-up as compared to students who were not provided access to the CYDU.

Official Title
-----------------
Randomized Controlled Trial of a Brief Personalized Feedback Intervention in University Students

Conditions
-----------------
Risky Alcohol Consumption

Intervention / Treatment
-----------------
* Behavioral: Check Your Drinking University version


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AUDIT-C score of 4 or more at baseline Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Provided access to the Check Your Drinking University version (CYDU). | Behavioral: Check Your Drinking University version<br>* The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).<br>|
| No Intervention: Control<br>No invention control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alcohol Use Disorders Identification Test - Consumption scale (AUDIT-C scale) | AUDIT-C is a scale that is a composite of three items - frequency of alcohol use, drinks per drinking day, and frequency of 5+ drinking occasions. Scores ranges from 0 to 12 with higher scores indicating more severe alcohol problems. | 6 weeks |
Lactate Clearance in Hospital-acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
There is no clear consensus on the use of pneumonia severity index (PSI) developed for community-acquired pneumonia in hospital-acquired pneumonia cases. In another aspect, PSI is a relatively difficult scoring system that includes many parameters. This study evaluated whether lactate clearance could be used as a mortality marker instead of PSI in hospital-acquired pneumonia. As a result, lactate clearance was lower in the mortal group and when the diagnostic statistics were evaluated, it was seen that the sensitivity and specificity rates were significantly higher. In conclusion, lactate clearance has been evaluated as a strong predictor of mortality in hospital-acquired pneumonia.

Official Title
-----------------
The Prognostic Value of Lactate Clearance in Hospital-acquired Pneumonia

Conditions
-----------------
Pneumonia, Mortality, Lactate, Prognosis

Intervention / Treatment
-----------------
* Diagnostic Test: Lactate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 and over age, hospital-acquired pneumonia, emergency department admissions Exclusion Criteria: Patients who are pregnant or lactating, under 18 years of age, in the healthcare-associated pneumonia group, had mechanical ventilation at the last hospitalization, whose lactate level could not be studied for any reason at admission and 6th hour, had missing data used in pneumonia severity index calculation and/or who did not accept to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = [(Initial lactate - 6th hour lactate) / Initial lactate] * 100|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | 28-day mortality | 28 day |
Allogene MSCs Transplantation in Liver for Patients With Chronic Liver Diseases Through Portal Vein by Ultrasound Guiding

Study Overview
=================
Brief Summary
-----------------
Allogene MSCs transplantation will be performed in patients with chronic liver diseases through portal vein by ultrasound guiding and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Conditions
-----------------
Allogene Transplantation, Chronic Liver Diseases Patients, Through Portal Vein by Ultrasound Guiding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease. age: 15-65 years old. Exclusion Criteria: pregnant women and women in lactation. other systems and organs disfunction space-occupying lesion were found in liver. concurrent infection with HIV and other immunodeficiency diseases. DIC and active bleeding were confirmed.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| transplantation<br> | |
| control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation |  | 1-8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allogene MSCs, transplantation, chronic liver diseases, portal vein
A Cluster Randomized Trial to Improve Weaning and Extubation From Mechanical Ventilation in Community Hospitals

Study Overview
=================
Brief Summary
-----------------
Protocol directed weaning has been shown to reduce the duration of mechanical ventilation for patients admitted to the intensive care unit (ICU) of tertiary centres. However, this benefit has not previously been studied in a community hospital setting. We therefore sought to evaluate the impact of an evidence-based weaning guideline on the outcomes for patients receiving mechanical ventilation in the ICUs of community hospitals in a cluster randomized controlled trial involving 11 community hospitals.

Official Title
-----------------
A Cluster Randomized Trial to Improve Weaning and Extubation From Mechanical Ventilation in Community Hospitals

Conditions
-----------------
Respiration, Artificial

Intervention / Treatment
-----------------
* Procedure: Evidence based weaning protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients ventilated for more than 24 hours Exclusion Criteria: patients less than 16 years of age patients who receive only non-invasive ventilation patients chronically ventilated at time of ICU admission patients who will not be candidates for weaning from ventilation at time of admission If withdrawl of life support is imminent at the point the patient has been ventilated for 24 hours

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Evidence based weaning protocol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU length of stay |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of ventilation |  |  | 
| length of hospital stay |  |  | 
| complications (re-intubation within 48 hours, pneumonia within 48 hours) |  |  | 
| ICU mortality |  |  | 
| Hospital mortality |  |  | 
| ICU readmissions |  |  | 
| Qulaity of life |  |  |
Korean Coronary Overlapping Stenting Registy

Study Overview
=================
Brief Summary
-----------------
The Korean Coronary Overlapping Stenting Registry is a multicenter database which includes percutaneous intervention using drug-eluting stents from cardiovascular centers in eight affiliated hospitals of The Catholic University of Korea

Detailed Description
-----------------
The Korean Coronary Overlapping Stenting Registry is a multi-center, real-world of drug-eluting stent overlap.

Official Title
-----------------
Korean Coronary Overlapping Stenting Registy

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 18 years Drug-eluting stent overlap Exclusion Criteria: Overlap with previous stent Cardiogenic shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of the composite outcomes of cardiac death, myocardial infarction, and target lesion revascularization |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac death |  | 3 years | 
| Myocardial infarction |  | 3 years | 
| Target lesion revascularization |  | 3 years | 
| stent thrombosis |  | 3 years |
GnRH Agonist and Intrauterine Insemination

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Official Title
-----------------
Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial

Conditions
-----------------
Intrauterine Insemination

Intervention / Treatment
-----------------
* Drug: Tryptorelin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women < 38 years old Bilateral tubal patency confirmed by hysterosonography Normal ultrasound scan of uterus and ovaries Normal day 3 basal hormones Motile sperm count after capacitation ≥ 3 mill/ml Exclusion Criteria: Endometriosis Polycystic ovary syndrome Uterine disease (polyps, myomas and müllerian diseases)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tryptorelin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intrauterine insemination, GnRH agonist, implantation
Hot AXIOS System Japan Post Market Survey

Study Overview
=================
Brief Summary
-----------------
To detect information of Adverse Events and Device Malfunctions under real world medical condition in Japan.

Official Title
-----------------
A Post Market Survey to Detect Information of Adverse Events and Device Malfunctions of AXIOS Stent and Electrocautery Enhanced Delivery System Under Real World Medical Condition in Japan

Conditions
-----------------
Pancreatic Pseudocyst Infection, Pancreatic Pseudocyst, Walled Off Necrosis Infection, Walled Off Necrosis

Intervention / Treatment
-----------------
* Device: EUS-guided fistulization AXIOS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who received implant procedure using study device at Japanese site. Exclusion Criteria: NA
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AXIOS Patient<br> | Device: EUS-guided fistulization AXIOS<br>* By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (Adverse Events and Device Malfunction) |  | From implant procedure to 7 days after removal | 
| Placement success | AXIOS stent is placed in an appropriate position using the delivery system. | During implant procedure | 
| Stent retention | AXIOS stent stays at the position where it was implanted during the implant procedure. | From implant procedure to removal (a maximum of 60 days) | 
| Stent lumen patency | The lumen of AXIOS stent is patent, and it can be used for drainage etc. | From implant procedure to removal (a maximum of 60 days) | 
| Decreased cyst size |  | From implant procedure to final observation (a maximum of 60 days) | 
| Removal success | AXIOS stent can be removed using standard endoscopic snares or forceps. | Removal procedure (a maximum of 60 days after implant procedure) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
WON, PPC
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Study Overview
=================
Brief Summary
-----------------
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Detailed Description
-----------------
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Official Title
-----------------
Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Conditions
-----------------
Thyroid Neoplasms

Intervention / Treatment
-----------------
* Procedure: IMRT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence Exclusion Criteria: medullary or anaplastic thyroid cancer, unresectable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: IMRT|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| toxicity according to RTOG criteria |  |  | 
| locoregional control |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thyroid neoplasms, intensity modulated radiation, radiotherapy
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether combination oral contraceptive pill of norethindrone and ethinyl estradiol is effective in the treatment of primary dysmenorrhea.

Official Title
-----------------
Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Primary Dysmenorrhea.

Conditions
-----------------
Dysmenorrhea

Intervention / Treatment
-----------------
* Drug: IKH-01
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary dysmenorrhea Exclusion Criteria: severe hepatopathy pregnant woman

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IKH-01<br>ethinyl estradiol 0.035mg and norethisterone 1mg | Drug: IKH-01<br>* ethinyl estradiol 0.035mg and norethisterone 1mg<br>|
| Placebo Comparator: Placebo<br>Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg | Drug: Placebo<br>* Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Response to Treatment for Primary Dysmenorrhea, as Evaluated by Difference of Total Dysmenorrhea Score (Baseline/Pretreatment-End of Treatment) | The detail of dysmenorrhea score that was used in this study is the following. These subscales summed for a total dysmenorrhea score (minimum 0 to maximum 6). Pain score None 0 : None Mild 1 : There are some troubles for work Moderate 2 : Needing to rest in bed and/or affecting work Severe 3 : Morre than 1 day in bed and not possible to work Drug score (during a menstrual period) None 0 : None Mild 1 : taking analgesics for 1 days Moderate 2 : taking analgesics for 2 days Severe 3 : taking analgesics more than 3 days | 16weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in the VAS of Primary Dysmenorrhea (Baseline/Pretreatment-dnd of Treatment) | VAS stands for Visual Analogue Scale of pain. The scale was rated as a graphic rating scale. as a 100mm baseline from 0:No pain to 100:Worst possible pain. | 16weeks |
Evidence Based Algorithm for Proximal Humerus Fractures

Study Overview
=================
Brief Summary
-----------------
Proximal humerus fractures are particularly frequent injuries and represent 6% of all fractures with an overall incidence of 63/100.000 in human. The goal is to assess our institutional evidence based algorithm for treatment of proximal humeral fractures. Objective(s): Test the algorithm in terms of clinical applicability and clinical outcome Compare general outcome and general complication/revision rate to the literature. Inclusion / Exclusion criteria: Inclusion: All patients with an acute proximal humeral fracture (not older than 48 hours) admitted to our institution later than 1.1.2014. Exclusion: Multilevel and pathological fractures are excluded. Terminally ill patients and those not being able, or willing to sing the informed consent. Project Centre(s): Single-centre. Statistical Considerations: Standard descriptive statistics will be performed using R-statistics program. Considering the population of 160 patients, we will be able to detect differences in proportions as low as 0.15 with power 82% and alpha = 0.05. Other methodological Considerations: Terms applicability of a treatment protocol and adhesion to protocol are not well defined for decision making in orthopaedic surgery.

Official Title
-----------------
Evidence Based Algorithm to Treat Patients With Proximal Humerus Fractures - A Prospective Study With Early Clinical and Overall Performance Results

Conditions
-----------------
Proximal Humeral Fracture

Intervention / Treatment
-----------------
* Procedure: Therapy of proximal humeral fractures (irrespective conservative or operative)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute traumatic proximal humeral fracture Signed informed consent Exclusion Criteria: Fracture older than 48 hours at admission Multilevel fractures of the humerus Pathological fractures Terminally ill patients.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Therapy of proximal humeral fractures (irrespective conservative or operative)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Constant Score | Point 0-100 | One year |